Theorem Clinical Research appoints vp of global regulatory affairs

Brian Bollwage is a food and drug law expert

Theorem Clinical Research, a US contract research organisation (CRO), has appointed Brian Bollwage to the position of vice president of global regulatory affairs.

Bollwage was previously director of global regulatory science at Bristol-Myers Squibb and executive director and regulatory counsel of global regulatory intelligence at i3 Research.

He is a food and drug law expert and a graduate of Rutgers Law School. He currently serves as an associate professor of food and drug law at Temple University in Philadelphia.

You may also like

Research & Development

Chiltern to purchase Theorem Clinical Research

To expand its global reach and scientific expertise
Research & Development

Theorem opens clinical supplies facility in Frankfurt, Germany

The expansion will offer both ambient and refrigerated storage space
Research & Development

Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing

Helping biopharma labs reach new heights in analytical performance
Regulatory

Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria

Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
Regulatory

Pfizer strikes landmark deal with US government to lower drug prices

The agreement ensures Americans pay less for medicines while giving Pfizer tariff certainty and a clear pricing framework, enabling $70bn in US investment and a renewed focus on next-generation therapies in cancer, obesity, vaccines and immunology
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Subscribe now